Bretolap 250 mg Tablet is an anti-cancer medicine used in the treatment of Breast cancer. The abnormal growth of cancer (malignant) cells in the breast is known as breast cancer. Bretolap 250 mg Tablet is used in combination with capecitabine for treating patients with HER2-positive advanced or metastatic breast cancer who have received prior treatment, including anthracycline, taxane, and trastuzumab. This medicine is also used in combination with letrozole for the treatment of hormone receptor-positive metastatic breast cancer in patients with HER2-positive (human epidermal growth factor receptor 2) for whom hormonal therapy is indicated.

Bretolap 250 mg Tablet contains Lapatinib as an active ingredient which belongs to the class of kinase inhibitors. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

Bretolap 250 mg Tablet may cause certain side effects such as diarrhea, fatigue, nausea, rash, indigestion, loss of appetite, headache, vomiting, weakness, mouth sores, hair loss, dry skin, myalgia, and allergic reactions. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. Bretolap 250 mg Tablet should be taken as advised by your doctor. Take the medicine around the same time daily. Do not skip any dose; if you forget any dose, try to take it as soon as you remember unless it is time for your next dose. Do not double the dose.

Bretolap 250 mg Tablet should be avoided if you are allergic to it or any other components of this medicine. Before starting the treatment, let your doctor know about your complete medical history and medication history, including vitamin and herbal supplements. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease before taking Bretolap 250 mg Tablet . Bretolap 250 mg Tablet is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. 

Bretolap 250 mg Tablet contains Lapatinib as an active ingredient, which is used in combination with capecitabine for treating patients with HER2-positive advanced or metastatic breast cancer who have received prior treatment. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

Bretolap 250 mg Tablet should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Bretolap 250 mg Tablet may cause left ventricular ejection fraction, prolonged QT interval, hepatotoxicity, interstitial lung disease, pneumonitis, severe diarrhoea, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Bretolap 250 mg Tablet is known to cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Bretolap 250 mg Tablet should be given to children only if prescribed by the paediatrician. Bretolap 250 mg Tablet is not recommended for use in children as the safety and efficacy are not established. Avoid alcohol consumption and smoking, as it can lead to serious adverse effects.